Factor VIIa

Factor VIIa is the active, working form of Factor VII. Think of Factor VII like a key that unlocks the door to blood clotting. Factor VIIa is the key that unlocks the door to activate Factor X, which is another important part of the clotting process.

Brand names:NovoSeven RT, Sevenfact
Medication

What people taking Factor VIIa report

Every report comes from a Lived member, sent anonymously.

Have you tried Factor VIIa for Factor VII Deficiency?

NameHow it went

About Factor VIIa

What It's For

Factor VIIa is a laboratory-made (recombinant) form of activated factor VII, one of the proteins the body uses to form blood clots. In the US it is sold as NovoSeven RT and Sevenfact. It is a specialist medicine for a few rare bleeding disorders, used when the usual treatments cannot do the job. Its main use is in hemophilia A or B with inhibitors. Hemophilia is normally treated by replacing the missing clotting protein, factor VIII or factor IX. Some people's immune systems make antibodies, called inhibitors, that neutralize the replacement factor. Factor VIIa is known as a bypassing agent because it helps blood clot by a route that does not need factor VIII or IX. NovoSeven RT is approved for adults and children with inhibitors, both to treat bleeding episodes and to prevent bleeding during surgery. Sevenfact is approved only to treat bleeding episodes, in people 12 and older with inhibitors. NovoSeven RT is also approved for three other rare conditions. Congenital factor VII deficiency is an inherited shortage of factor VII itself. Glanzmann thrombasthenia is an inherited disorder in which platelets cannot clump together to plug a wound; here factor VIIa is used when platelet transfusions no longer work. Acquired hemophilia develops in adults with no earlier bleeding problems, when the immune system starts attacking the body's own factor VIII. Sevenfact is not approved for factor VII deficiency. Hospitals have also tried factor VIIa for heavy bleeding after surgery, injury or bleeding in the brain in people without a bleeding disorder. Across the randomized trials, it did not improve survival and it increased clots in arteries, especially in people 65 and older. A major review concluded that use outside the approved conditions should be limited to clinical trials.

How It Works

Clotting is a chain reaction. When a blood vessel is injured, a protein called tissue factor is exposed, and factor VII attaches to it. This activated pair switches on factor X, which leads to thrombin, the enzyme that turns the blood protein fibrinogen into the fibrin strands that hold a clot together. Factors VIII and IX normally drive a second, more powerful route to the same step. When either is missing or blocked by inhibitors, clots form too slowly and too weakly to stop bleeding. Given as a medicine, factor VIIa switches on factor X both through tissue factor and directly on the surface of activated platelets gathered at the injury. That path to a clot skips factors VIII and IX, so it still works when inhibitors are present. The medicine is cleared from the blood within a few hours, which is why a bleed often needs repeated doses.

Dosage & Administration

Factor VIIa comes as a powder that is mixed with a supplied liquid and injected slowly into a vein over a few minutes. In hospital, nurses give it. It can also be given at home by the patient or a family member after training from the care team, and the patient instructions say not to use the equipment without that training. The dose is calculated from body weight and depends on the brand, the condition and how serious the bleed is. Treatment is meant to start as soon as a bleed begins. In hemophilia with inhibitors, doses are usually repeated every two to three hours until bleeding stops, and a serious bleed may need further doses at longer intervals after that. People with factor VII deficiency need much smaller doses, spaced four to six hours apart. Sevenfact has its own dosing schedule, different from NovoSeven RT's, so a plan written for one brand does not carry over to the other. Surgery needs a schedule of doses before, during and after the operation, planned by the hematology team. At home, follow the written treatment plan from the hemophilia treatment center rather than adjusting doses on your own.

Side Effects

In Sevenfact studies, the most common reactions were headache, dizziness, fever, and discomfort or bruising where the needle went in. NovoSeven trials also reported fever and raised blood pressure. The most important risk is an unwanted blood clot, the subject of an FDA boxed warning for both brands. Clots can form in veins or arteries and cause problems such as a clot in the leg or lung, chest pain from the heart, or a stroke. In NovoSeven trials, clots followed about 2 in 1,000 treated bleeds in congenital hemophilia but affected about 4 percent of people treated for acquired hemophilia. Call 911 for new chest pain, shortness of breath, sudden weakness or numbness, confusion, or trouble speaking. New swelling and pain in an arm, a leg or the abdomen also needs medical care right away. Serious allergic reactions, including anaphylaxis, can happen but are uncommon. If hives, chest tightness, wheezing, swelling of the mouth or throat, or faintness start during or after an infusion, stop the infusion and call 911.

Interactions & Warnings

Factor VIIa should not be given at the same time as activated prothrombin complex concentrate (aPCC, sold as FEIBA), the other main bypassing agent for hemophilia with inhibitors, because the combination raises the risk of serious clots. If you carry both at home, your plan should say clearly which one to use for a bleed. Clot risk is also higher in older adults, in people with heart disease, narrowed arteries, a past stroke or past clots, and when other clot-promoting treatments are given alongside it. The prescriber weighs this before treatment and watches for clots during it. The two brands are made differently, which matters for allergies. NovoSeven RT is produced in hamster cells and can contain traces of mouse, hamster and cow proteins, so people allergic to those proteins have a higher risk of reaction. Sevenfact is produced in genetically engineered rabbits and must not be used by anyone allergic to rabbits or rabbit proteins. A known allergy to casein, a milk protein, also raises the risk of a reaction to Sevenfact. There are no adequate studies of factor VIIa in pregnancy, so anyone who is pregnant or planning pregnancy should discuss bleeding plans with the hematology team.

What to Expect

Factor VIIa is used to treat bleeds and cover operations, not as ongoing preventive treatment. Success is judged by whether the bleeding stops. Standard clotting blood tests, which measure how many seconds a blood sample takes to clot, can change after a dose but do not reliably show whether it is working. In NovoSeven trials of joint and muscle bleeds, most people's response was clear within eight doses, while severe bleeds needed more. Once bleeding is under control, the team keeps further doses to a minimum. The right length of treatment after a bleed stops has not been studied, and in trials most of the people who had side effects had received more than 12 doses. If a bleed is not settling as the plan expects, contact the treatment center promptly. The Sevenfact label advises considering another treatment if bleeding is not controlled within 24 hours. In factor VII deficiency, a weaker response than usual can mean the body has made antibodies against factor VII, so the team checks clotting levels before and after treatment. In acquired hemophilia, factor VIIa only controls bleeding. Separate medicines that calm the immune system are used to clear the antibodies against factor VIII. The typical time to remission is about five weeks, though it varies widely.

Questions to Ask Your Doctor

  1. 1.Why is factor VIIa the right bypassing agent for me rather than aPCC or another option?
  2. 2.How many doses should I give at home for a bleed, and at what point should I call the treatment center?
  3. 3.Do any of my health conditions raise my risk of a blood clot, and what signs should I watch for?
  4. 4.Which brand am I using, and would my dosing plan change if my supply switched to the other one?
  5. 5.How will we decide that a bleed is controlled and it is time to stop dosing?

Last reviewed • Oct 2026

Educational content, not medical advice.